Please login to the form below

Not currently logged in
Email:
Password:

Sparsentan

This page shows the latest Sparsentan news and features for those working in and with pharma, biotech and healthcare.

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets. Sparsentan has potential to become a blockbuster FSG drug, according to analysts. ... Now, the company says a phase II trial of sparsentan in focal segmental glomerulosclerosis (FSG), a rare

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics